Quin Wills is the CSO and Co-Founder of Ochre Bio, a pioneering biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for liver health challenges ranging from increasing donor liver supply to reducing cirrhosis complications.
In addition to his work at Ochre, Quin is also a highly accomplished academic with a medical degree from Witwatersrand University and doctoral degrees from Cambridge and Oxford in computational biology, mathematics, and statistical genomics. Along with his academic accomplishments, Quin also co-founded SimuGen and has worked at the University College London, the Mayo Clinic, and Novo Nordisk before he went on to co-found Ochre Bio. Quin's diverse experiences offer a wealth of insights that everyone can draw inspiration from.
Quin’s Journey Through Y Combinator | The Role of Empathy in Team Dynamics | Adapting in a Shifting Biotech Industry | Ochre Bio’s Fundraising Journey & Future Plans
University of Oxford’s Single Cell Consortium | The Pitfalls of Californian Entrepreneurships | Dinner Table Origins of Ochre Bio | The Laws that Guide Ochre Bio
Pursuing Dual Masters at Oxford & Cambridge | Moving from Genomics to RNA Research | Balancing Academia & Entrepreneurship | The Challenges of Product-Market Fit in Biotech
Childhood Moments in Johannesburg | A Passion for Science Grows with an Evolving Society | Academic Experience in Biology and Genetics | Exposure to Bioinformatics and Big Data
Start listening to TBSP episodes on your favorite platform. Subscribe to stay up to date on new episodes.
